Embattled drugs testing company, Huntingdon Life Sciences, secured its financial lifeline last week only by persuading the Financial Services Authority to waive a rule requiring companies to disclose names of lenders in annual reports.
Run by accountants Brian Cass and Andrew Baker, managing director and chairman respectively, HLS took the unusual step to ensure its US backers remained anonymous as animal rights protestors stepped up their campaign against the company.
An FSA spokesman would not confirm details but said that in general such waivers were granted to a company in ‘severe financial distress’ where disclosure would be seriously detrimental to the company and that the omission of such information would not mislead the market.
The Royal Bank of Scotland, which wrote off £11.6m as part of the deal, last week suffered demonstrations outside its London and Edinburgh offices. Protestors, led by Stop Huntingdon Animal Cruelty, have now set their sights on HLS’ customers including GlaxoSmithKline. Deloitte & Touche, Huntingdon’s auditor, declined to say whether it had stepped up security at its offices in the face of possible protests.
Company information for HLS can be viewed at www.huntingdon.com.
Andrew Tyrie airs views on the Finance Bill, 'Making Tax Policy Better' report, and Brexit
In our latest managing partner Q&A looking towards 2017, CVR Global's Richard Toone talks about recruitment, and the potential threat of competition from the legal sector, as key issues for the firm in the coming year
Deloitte to avoid tendering for government contracts over the next six months, to appease Theresa May following consultant's report that painted a less-than-flattering picture of Brexit plans
In our first Q&A looking towards 2017, Menzies senior partner Julie Adams flags up increasing digitisation, aligned with more hands-on consultative services, as the key mix for her practice